MN-001 (Tipelukast) - (NATG-202)

May 26, 2026: MediciNova, Inc. (NASDAQ: MNOV; TSE: 4875) reported completion of last patient last visit (LPLV) in its Phase 2 trial MN-001-NATG-202 evaluating MN-001 (tipelukast) for hypertriglyceridemia and nonalcoholic fatty liver disease (NAFLD) associated with type 2 diabetes mellitus (T2DM). The multicenter, randomized, double-blind, placebo-controlled study randomized patients 1:1 to MN-001 500 mg/day or placebo for 24 weeks. Co-primary endpoints are change from baseline at Week 24 in liver fat content measured by controlled attenuation parameter (CAP) score and change from baseline in fasting serum triglycerides; secondary endpoints include safety/tolerability and lipid profile changes (HDL-C, LDL-C, total cholesterol). Top-line data are expected in Q3 2026.